CLPT Earnings Date: Mar 16, 2027 (Estimated) — ClearPoint Neuro, Inc.
NASDAQ · Healthcare · Medical Devices
Updated
When is CLPT's next earnings date?
ClearPoint Neuro, Inc. (CLPT) is expected to report Q4 2026 earnings on Tuesday, March 16, 2027 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.29 on revenue of $13.8M.
How did CLPT do in its last earnings report?
In its most recent report on Oct 28, 2026 (Q3 2026), ClearPoint Neuro, Inc. posted EPS of -$0.24 versus the -$0.32 estimate, a beat of 23.8%. Revenue was $12.1M against a $12.3M estimate. The stock's 1-day post-earnings move was +1.2%.
How much does CLPT stock move after earnings?
CLPT beat EPS estimates in 1 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 11.7% (up or down) in the day after earnings.
About ClearPoint Neuro, Inc.
ClearPoint Neuro, Inc. is a medical technology firm primarily operating within the United States. The company specializes in developing and commercializing sophisticated systems that facilitate minimally invasive brain surgeries, guided by real-time magnetic resonance imaging (MRI) during the procedure. Among its core offerings is the ClearPoint system, designed for the precise placement of deep brain stimulation electrodes, biopsy needles, and for the controlled infusion of medications and laser catheters directly into the brain. It also provides the ClearPoint Neuro Navigation System, which is specifically engineered for MRI suite environments. ClearPoint Neuro maintains strategic partnerships and licensing agreements with prominent institutions and companies, including Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and the University of California, San Francisco. Initially established in 1998 and headquartered in Solana Beach, California, the company operated as MRI Interventions, Inc. before rebranding to ClearPoint Neuro, Inc. in February 2020.
🤖 AI Earnings Analysis
ClearPoint Neuro’s healthcare-device growth is encouraging, with revenue up 33% to $12M, but it missed estimates and losses widened to $0.24 per share despite an $0.08 EPS beat; profitability remains distant.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-28 | Q3 2026 | -0.32 | -0.24 | +23.81% | $12.1M | ✅ Beat | +1.23% | — | — |
| 2026-08-03 | Q2 2026 | -0.28 | -0.38 | -35.71% | $10.9M | ❌ Miss | -16.29% | -5.27% | -3.12% |
| 2026-05-13 | Q1 2026 | -0.27 | -0.32 | -18.52% | $12.1M | ❌ Miss | +4.76% | -8.12% | +10.25% |
| 2026-03-17 | Q4 2025 | -0.21 | -0.23 | -9.52% | $10.4M | ❌ Miss | -13.93% | -15.59% | -5.91% |
| 2025-11-06 | Q3 2025 | -0.20 | -0.21 | -5.00% | $8.9M | ❌ Miss | -13.27% | -14.98% | -24.90% |
| 2025-08-12 | Q2 2025 | -0.20 | -0.21 | -5.00% | $9.2M | ❌ Miss | +13.09% | -0.76% | +5.22% |
| 2025-02-26 | Q4 2024 | -0.16 | -0.20 | -25.00% | $7.8M | ❌ Miss | -17.51% | -17.71% | -27.87% |
| 2024-11-07 | Q3 2024 | -0.17 | -0.18 | -5.88% | $8.1M | ❌ Miss | -13.19% | -16.24% | +9.24% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q3 FY26 · $9.6M total
| Segment | Share | Revenue | YoY | Q3 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Biologics And Drug Delivery | 51.2% | $4.9M | +11.2% | $4.4M | $4.7M | $4.7M | $4.4M |
| Capital Equipment And Software | 18.2% | $1.7M | +68.0% | $831K | $517K | $1.0M | $1.0M |
| Capital Equipment And Software - Systems and Software Products | 13.3% | $1.3M | +96.0% | $552K | $234K | $694K | $647K |
| Biologics And Drug Delivery - Disposable Products | 12.4% | $1.2M | -8.3% | $2.1M | $1.8M | $1.9M | $1.3M |
| Capital Equipment And Software - Services | 5.0% | $474K | +21.5% | $279K | $283K | $350K | $390K |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.